BSE Live
Apr 20, 13:16Prev. Close
29.75
Open Price
29.24
Bid Price (Qty.)
29.17 (155)
Offer Price (Qty.)
29.24 (200)
NSE Live
Apr 20, 13:15Prev. Close
29.89
Open Price
29.30
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
31.97 (1)
| Key Financial Ratios of Mangalam Drugs & Organics (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 4.37 | -5.72 | 0.80 | 12.42 | 17.67 | |
| Diluted EPS (Rs.) | 4.37 | -5.72 | 0.80 | 12.42 | 17.67 | |
| Cash EPS (Rs.) | 14.72 | 3.53 | 7.74 | 18.89 | 23.47 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 93.92 | 89.93 | 96.00 | 95.12 | 82.74 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 93.92 | 89.93 | 96.00 | 95.12 | 82.74 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 201.05 | 232.87 | 235.18 | 284.98 | 240.17 | |
| PBDIT/Share (Rs.) | 22.93 | 11.05 | 16.40 | 31.05 | 36.66 | |
| PBIT/Share (Rs.) | 12.59 | 1.81 | 9.45 | 24.57 | 30.86 | |
| PBT/Share (Rs.) | 3.15 | -6.99 | 1.40 | 17.52 | 24.97 | |
| Net Profit/Share (Rs.) | 4.37 | -5.72 | 0.80 | 12.42 | 17.67 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 11.40 | 4.74 | 6.97 | 10.89 | 15.26 | |
| PBIT Margin (%) | 6.26 | 0.77 | 4.02 | 8.62 | 12.84 | |
| PBT Margin (%) | 1.56 | -2.99 | 0.59 | 6.14 | 10.39 | |
| Net Profit Margin (%) | 2.17 | -2.45 | 0.34 | 4.35 | 7.35 | |
| Return on Networth / Equity (%) | 4.65 | -6.35 | 0.83 | 13.05 | 21.35 | |
| Return on Capital Employed (%) | 11.41 | 1.62 | 7.70 | 19.61 | 31.47 | |
| Return on Assets (%) | 1.92 | -2.53 | 0.35 | 5.98 | 10.64 | |
| Total Debt/Equity (X) | 0.55 | 0.62 | 0.45 | 0.48 | 0.44 | |
| Asset Turnover Ratio (%) | 0.89 | 1.03 | 1.08 | 1.53 | 1.54 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.08 | 1.10 | 1.25 | 1.40 | 1.23 | |
| Quick Ratio (X) | 0.33 | 0.42 | 0.42 | 0.50 | 0.68 | |
| Inventory Turnover Ratio (X) | 2.43 | 2.82 | 2.18 | 3.86 | 4.15 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 196.07 | 233.59 | 220.52 | 233.04 | 214.80 | |
| EV/Net Operating Revenue (X) | 0.62 | 0.63 | 0.59 | 0.52 | 0.57 | |
| EV/EBITDA (X) | 5.40 | 13.35 | 8.50 | 4.74 | 3.70 | |
| MarketCap/Net Operating Revenue (X) | 0.37 | 0.40 | 0.42 | 0.36 | 0.41 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | 0.79 | 1.03 | 1.02 | 1.08 | 1.20 | |
| Price/Net Operating Revenue | 0.37 | 0.40 | 0.42 | 0.36 | 0.41 | |
| Earnings Yield | 0.06 | -0.06 | 0.01 | 0.12 | 0.18 |
20.01.2026
Mangalam Drugs Consolidated December 2025 Net Sales at Rs 58.49 crore, down 34.07% Y-o-Y
20.01.2026
Mangalam Drugs Standalone December 2025 Net Sales at Rs 58.49 crore, down 34.07% Y-o-Y
25.11.2025
Mangalam Drugs Consolidated September 2025 Net Sales at Rs 49.54 crore, down 38.03% Y-o-Y
24.11.2025
Mangalam Drugs Standalone September 2025 Net Sales at Rs 49.54 crore, down 38.03% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth